TipRanks
Akari Therapeutics (DE:CLA1)
FRANKFURT:CLA1
Germany Market
CLA1
Akari Therapeutics
RESEARCH TOOLSreports

Akari Therapeutics (CLA1) Income Statement

0 Followers

Akari Therapeutics Income Statement

Last quarter (Q2 2026), Akari Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Akari Therapeutics's net income was $-4.81M. See Akari Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Mar 23Mar 22
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 17.27M$ 21.64M$ 16.81M$ 23.09M$ 17.21M
Depreciation and Amortization
$ 0.00$ 14.00K$ 4.00K$ 4.00K$ 4.13K
EBITDA
$ -17.35M$ -19.53M$ -10.00M$ -17.74M$ -17.42M
Operating Income
$ -17.27M$ -21.64M$ -16.81M$ -23.09M$ -17.21M
Other Income/Expenses
$ -1.03M$ 1.85M$ 6.80M$ 5.34M$ -210.10K
Pretax Income
$ -18.30M$ -19.79M$ -10.01M$ -17.75M$ -17.42M
Net Income
$ -17.30M$ -19.79M$ -10.01M$ -17.75M$ -17.42M
Per Share Metrics
Basic EPS
$ -20.80K$ -132.80K$ -163.20K$ -455.20K$ -649.60K
Diluted EPS
$ -20.80K$ -132.80K$ -163.20K$ -455.20K$ -649.60K
Weighted Average Shares Outstanding
 21.04K 5.97K 2.45K 1.56K 1.07K
Weighted Average Shares Outstanding (Diluted)
 21.04K 5.97K 2.45K 1.56K 1.07K
Currency in USD

Akari Therapeutics Earnings and Revenue History